🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Netherlands
Clinical trial register · European Union · CTIS

Clinical Trials in Netherlands

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 21 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524 Belgium 426 Czechia 327
All 28 states
95 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults
2025-522930-29-00Incomplete Response - Major Depressive Disorder (IR-MDD)
Otsuka Pharmaceutical Development & Commercialization Inc.
Mental Disorders
Netherlands
31/10/2025
Phase I
AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
2025-521707-48-00KRAS Altered Advanced or Metastatic Solid Tumors
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase I
Research into the safety of a new agent (AX-5006) in people with and without Parkinson's disease.
2025-523254-14-00Parkinson's disease
Vertero Therapeutics Inc.
Nervous System Diseases
Netherlands
27/10/2025
Phase I
Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants
2025-521402-18-00Desmoid tumor
Springworks Therapeutics Inc.
Skin and Connective Tissue Diseases
Netherlands
22/10/2025
Phase I
Food effect and single- and multiple-ascending dose clinical trial of DF2755A in healthy participants
2025-522935-32-00interstitial cystitis/bladder pain syndrome
Dompe' Farmaceutici S.p.A.
Pathological Conditions, Signs and Symptoms
Netherlands
17/10/2025
Phase I
Study Investigating Tucatinib and Osimertinib Pharmacokinetics in Primary and Metastatic Brain Tumors: the STICK trial
2025-522128-28-00Breast cancer, Non small cell lung carcinoma, Glioblastoma
Amsterdam UMC Stichting
Neoplasms
Netherlands
15/10/2025
Phase I
A PHASE 1 TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PK, AND PD of AX-0810 IN HEALTHY PARTICIPANTS
2025-521876-77-00Cholestatic liver disease
ProQR Therapeutics VIII B.V.
Nutritional and Metabolic Diseases
Netherlands
14/10/2025
Phase I
A Study to Evaluate the Effect of TRIV-509 on Skin Barrier Function in Patients with Atopic Dermatitis.
2025-522635-34-00Atopic Dermatitis
Triveni Bio Inc.
Skin and Connective Tissue Diseases
Netherlands
07/10/2025
Phase I
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)
2025-521315-39-00Axial spondyloarthritis
Grey Wolf Therapeutics Limited
Hemic and Lymphatic Diseases
Belgium, Germany, Netherlands, Spain, Poland
06/10/2025
Phase I
A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors
2024-519622-20-00Advanced Solid Tumors Harboring RAS Mutation(S)
F. Hoffmann-La Roche AG
Neoplasms
Germany, Netherlands, Spain, Denmark, France, Belgium
22/09/2025
Phase I
Research into new test methods to measure pain with two existing drugs (nefopam and oxycodone)
2025-522389-66-00(Chronic) pain
Centre for Human Drug Research
Nervous System Diseases
Netherlands
22/09/2025
Phase I
An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE)
2025-520629-19-00HIV Infections
Viiv Healthcare UK Limited
Virus Diseases
Netherlands, Spain, Belgium, Denmark
22/09/2025
Phase I
A Study to Investigate the Effect of RO7504109 on Immune Cells in Healthy Participants
2025-522181-71-00Not Applicable (N/A)
F. Hoffmann-La Roche AG
Population Characteristics
Netherlands
16/09/2025
Phase I
A Phase 1/1b Study of IAM1363 in HER2 Cancers
2024-519188-17-00Relapsed/refractory malignancy with documented diagnosis of…
Iambic Therapeutics Inc.
Neoplasms
Spain, France, Ireland, Italy, Netherlands
11/09/2025
Phase I
A study investigating the safety, absorption, and elimination of NT 0150, a new compound that may potentially be used in the treatment of brain disorders, like Alzheimer’s disease and Parkinson’s disease.
2024-520142-32-00Cryopyrin associated periodic syndrome
Nodthera Limited
Immune System Diseases
Netherlands
05/09/2025
Phase I
Nebulised lIposomal aMphotericin B in chronic pUlmonary aSpergillosis: a deposition study
2025-521770-34-00Chronic pulmonary aspergillosis
Radboud universitair medisch centrum Stichting
Bacterial Infections and Mycoses
Netherlands
04/09/2025
Phase I
A study investigating the safety, tolerability, pharmacokinetics (absorption, distribution, metabolism and elimination) and effect of single and multiple doses of MTX46943, a new compound that may potentially be used in the treatment of Alzheimer’s disease and other neurological disorders
2025-522368-34-00Alzheimer’s Disease
Muna Therapeutics ApS
Nervous System Diseases
Netherlands
04/09/2025
Phase I
Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis
2025-521295-60-00Sporadic Amyotrophic Lateral Sclerosis
Eli Lilly & Co.
Nervous System Diseases
Belgium, Spain, Netherlands, Germany
02/09/2025
Phase I
A study comparing different RO7269162 capsules and investigating the effect of food on the uptake, breakdown, and elimination of RO7269162 in Healthy Participants
2025-520616-33-00Not Applicable
F. Hoffmann-La Roche AG
Population Characteristics
Netherlands
29/08/2025
Phase I
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
2024-519157-10-00Systemic Lupus Erythematosus, Sjogren's disease
AbbVie Deutschland GmbH & Co. KG
Immune system processes
Netherlands, France
28/08/2025
Rows per page Showing 76–95 of 95
Previous 2 3 4
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-europe/country/netherlands

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.